Research programme: cancer therapeutics - Adocia

Drug Profile

Research programme: cancer therapeutics - Adocia

Alternative Names: Anticancer nanoparticles - Adocia; Cancer therapies - Adocia; DriveIn cancer therapeutics - Adocia; Ovarian cancer therapy - Adocia

Latest Information Update: 01 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adocia
  • Class Proteins; Small molecules
  • Mechanism of Action DNA intercalators; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Ovarian cancer; Solid tumours

Most Recent Events

  • 27 Jul 2016 Discontinued - Preclinical for Solid tumours and for Ovarian Cancer in France (Parenteral) before July 2016 - Adocia focusing on the development of treatment for diabetes only
  • 01 Nov 2014 Preclinical trials in Solid tumours and Ovarian cancer in France (Parenteral)
  • 09 Dec 2013 Adocia receives development and commercialisation rights to the DriveIn® nanotechnology from CNRS, University Bordeaux I and SATT Aquitaine in the field of healthcare
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top